Loading market dashboard
Verici Dx plc
VRCDFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
FRANKLIN, Tenn.--(BUSINESS WIRE)--In the first and last paragraphs, the text should read: Pre-Transplant Risk Assessment (instead of: Pre-Transplant Rejection Assessment). The updated release reads: VERICI DX ANNOUNCES PUBLICATION VALIDATING PRE-TRANSPLANT GENE SIGNATURE TEST FOR PREDICTING EARLY ACUTE REJECTION IN KIDNEY TRANSPLANT RECIPIENTS Test outperformed conventional risk metrics in predicting early acute rejection in the first two months following deceased donor kidney transplant Enable.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assa.
